1Department of Dermatology, Hamamatsu University School of Medicine, Japan.
Interleukin-2 (IL-2) therapy shows promise for malignant hemangioendothelioma (MHE). Studies reveal IL-2 recruits cytotoxic immune cells like NK cells to tumors, enhancing their ability to target cancer cells.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Observation:
Findings:
Implications: